Technetium (99mTc) votumumab

From WikiProjectMed
(Redirected from Votumumab)
Jump to navigation Jump to search
Technetium (99mTc) votumumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
Targettumor antigen CTAA16.88
Clinical data
ATC code
Legal status
Legal status
  • not marketed
Identifiers
CAS Number
ChemSpider
  • none
UNII
 ☒NcheckY (what is this?)  (verify)

Technetium (99mTc) votumumab (trade name HumaSPECT) is a human monoclonal antibody labelled with the radionuclide technetium-99m.[1][2] It was developed for the detection of colorectal tumors, but has never been marketed.[3]

The target of votumumab is CTAA16.88, a complex of cytokeratin polypeptides in the molecular weight range of 35 to 43 kDa, which is expressed in colorectal tumors.[4]

References

  1. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 13 (1). 1999.
  2. ^ Hendriks BS, Gaddy DF (2017). "Radiolabeled Antibody-Based Imaging in Clinical Oncology". In Olivier Jr KJ, Hurvitz SA (eds.). Antibody-Drug Conjugates: Fundamentals, Drug Development, and Clinical Outcomes to Target Cancer. Hoboken, New Jersey: John Wiley & Sons. p. 441. ISBN 978-1-119-06084-0.
  3. ^ "Public Statement on HumaSPECT" (PDF). European Medicines Agency (EMA_. 23 February 2004. Archived from the original (PDF) on 2007-06-10. Non-renewal of the marketing authorisation in the European Union
  4. ^ "Summary of Product Characteristics for HumaSPECT" (PDF). European Medicines Agency (EMA).


Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Stub icon

This nuclear medicine article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://mdwiki.org/wiki/Technetium_(99mTc)_votumumab"